Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triapine with Chemoradiation for Locally Advanced Cervical and Vaginal Cancer
NCT02595879Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2019
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of triapine in Cervical Cancer (CC) and vaginal cancer, sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose at 5 weeks, Dose-Limiting Toxicity at 5 weeks and 5 more. Started Sep 2019; status: active, not recruiting.
02
Drugs
triapine
03
Conditions
Cervical Cancer (CC)vaginal cancer
Beyond the preview
Go deeper on NCT02595879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02595879.